Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/29/2025

Management of Patients Requiring Both Anticoagulation and Antiplatelet Therapy

Clinical Context and Evidence

  • The European Society of Cardiology recommends that the combination of apixaban and clopidogrel be used in patients with atrial fibrillation requiring oral anticoagulation who undergo percutaneous coronary intervention (PCI) with stenting, due to the increased risk of bleeding 1
  • Dual antithrombotic therapy (apixaban + clopidogrel) is preferred over triple therapy in most cases to minimize bleeding, according to the European Heart Journal 1
  • The American Heart Association suggests that proton pump inhibitors (PPIs) reduce upper GI bleeding risk more effectively than H2 receptor antagonists, and are appropriate for patients with multiple bleeding risk factors receiving antithrombotic therapy 2

Risk Stratification

  • Advanced age is a high bleeding risk factor to consider when combining apixaban and clopidogrel, as stated by the American Heart Association 2
  • Concurrent use of anticoagulants, steroids, or NSAIDs increases the bleeding risk, according to the European Heart Journal 1, 2

Practical Management Algorithm

  • The European Society of Cardiology recommends confirming the indication for both anticoagulation and antiplatelet therapy, assessing bleeding risk, choosing the shortest appropriate duration, prescribing PPI prophylaxis, planning for de-escalation, and monitoring closely 1, 2
  • The American Heart Association suggests that PPI prophylaxis should be initiated for GI protection when combining apixaban and clopidogrel 1, 2